These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5149092)

  • 21. [Hypertriglyceridemia induced by carbohydrates in primary hyperlipoproteinemia].
    Lussier-Cacan S; Beaudoin R; Gattereau A; Davignon J
    Union Med Can; 1977 Apr; 106(4):474-84. PubMed ID: 860339
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus].
    Caporicci D; Mori A; Pepi R; Lapi E
    Clin Ter; 1979 Feb; 88(4):372-86. PubMed ID: 455913
    [No Abstract]   [Full Text] [Related]  

  • 23. Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.
    Aubry F; Lapierre YL; Noël C; Davignon J
    Ann Intern Med; 1971 Aug; 75(2):231-7. PubMed ID: 5558651
    [No Abstract]   [Full Text] [Related]  

  • 24. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
    Nikkilä EA; Ylikahri R; Huttunen JK
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental production of syndrome of obesity, hyperinsulinemia and hyperlipidemia in monkeys.
    Hamilton CL; Kuo PT; Feng LY
    Proc Soc Exp Biol Med; 1972 Jul; 140(3):1005-8. PubMed ID: 5039361
    [No Abstract]   [Full Text] [Related]  

  • 26. [The lipid reducing action of phenformin in primary type IV hyperlipoproteinaemia (author's transl)].
    Lang PD; Vollmar J; Klemens UH; von Löwis P; Gries FA; Koschinsky T; Huth K; Pilz E; Schlierf G; Kremer GJ; Lenhart P; Schwandt P; Hammerl H; Studlar M
    Dtsch Med Wochenschr; 1973 Nov; 98(48):2280-6. PubMed ID: 4762828
    [No Abstract]   [Full Text] [Related]  

  • 27. Liver scan in hyperlipoproteinemia.
    Sachs BA; Bardfeld PA; Bodian JE; Sugarman LA; Hellman L
    JAMA; 1974 Feb; 227(8):907-10. PubMed ID: 4590252
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of low sugar intake upon blood lipids and insulin levels of hyperlipemic subjects.
    Friedman M; Rosenman RH; Byers SO; Elevitch FR
    Proc Soc Exp Biol Med; 1970 Dec; 135(3):785-91. PubMed ID: 5486716
    [No Abstract]   [Full Text] [Related]  

  • 29. Familial hyper-pre-betalipoproteinemia with observations on the metabolism of endogenous particles.
    Rose HG
    J Lab Clin Med; 1970 Jul; 76(1):92-102. PubMed ID: 5425367
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
    Hermann LS; Karlsson JE; Sjöstrand A
    Eur J Clin Pharmacol; 1991; 41(3):263-5. PubMed ID: 1748145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diurnal patterns of blood sugar, plasma insulin, free fatty acid and triglyceride levels in normal subjects and in patients with type IV hyperlipoproteinemia and the effect of meal frequency.
    Schlierf G; Raetzer H
    Nutr Metab; 1972; 14(2):113-26. PubMed ID: 5051903
    [No Abstract]   [Full Text] [Related]  

  • 33. Change of lipoprotein pattern by clofibrate in hyperglyceridaemia and mixed hyperlipidaemia.
    Miettinen TA; Penttilä IM; Lampainen E
    Acta Med Scand; 1972 Sep; 192(3):177-82. PubMed ID: 4341290
    [No Abstract]   [Full Text] [Related]  

  • 34. Vascular and metabolic studies of amyotrophic lateral sclerosis. II. Lipid and carbohydrate metabolism.
    Gustafson A; Störtebecker P
    Neurology; 1972 May; 22(5):528-36. PubMed ID: 4673450
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapeutic effect of Ciba 13437-Su in 40 patients with familial essential hyperlipemia].
    Schönbeck M; Forster G; Hirzel H; Jakab T; Rosenmund H
    Dtsch Med Wochenschr; 1970 Aug; 95(35):1761-8. PubMed ID: 5451984
    [No Abstract]   [Full Text] [Related]  

  • 36. The prevalence of hyperlipidemia in a natural community.
    Gibson TC; Whorton EB
    J Chronic Dis; 1973 Apr; 26(4):227-36. PubMed ID: 4351694
    [No Abstract]   [Full Text] [Related]  

  • 37. Type V hyperlipoproteinaemia. Metabolic changes in hyperlipaemic and previously hyperlipaemic ("susceptible") male patients.
    Jacobsen BB
    Atherosclerosis; 1973; 17(3):471-81. PubMed ID: 4577010
    [No Abstract]   [Full Text] [Related]  

  • 38. [Proinsulin and insulin secretion in obese females before and after administration of metformin].
    Hausmann VL; Schubotz R
    Arzneimittelforschung; 1975 Apr; 25(4):668-75. PubMed ID: 1174086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of body weight changes on plasma lipids in patients with primary hyperlipoproteinemia.
    Lisch HJ; Bolzano K; Herbst M; Sailer S; Sandhofer F; Braunsteiner H
    Atherosclerosis; 1974; 19(3):477-84. PubMed ID: 4828569
    [No Abstract]   [Full Text] [Related]  

  • 40. [The therapeutic value of "Essential" phospholipids].
    Pristautz H
    MMW Munch Med Wochenschr; 1975 Apr; 117(14):583-6. PubMed ID: 806790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.